Abstract
Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes 1, 2 . We comprehensively profiled the genomic landscape of 42 benign and malignant tumors across 13 individuals from four multigenerational families. 5 Novel driver mutations were found in epigenetic modifiers DNMT3A and BCOR in 29% of benign tumors. Multi-level and microdissected sampling strikingly reveal that many clones with different DNMT3A mutations exist in these benign tumors, suggesting that intra-tumor heterogeneity is common. Integrated genomic and methylation profiling suggest that mutated DNMT3A drives tumorigenesis mechanistically through Wnt/ß-catenin pathway signaling. 10 Phylogenetic and mutational signature analyses confirm the phenomenon of benign pulmonary metastases from primary skin lesions. In malignant tumors, additional epigenetic modifiers MBD4, CREBBP, KDM6A and EP300 were mutated. We thus present epigenetic dysregulation as a driver in CCS tumorigenesis and propose this may account for the diverse histophenotypic patterns despite the paucity of mutations seen. These findings add novel 15 dimensions to existing paradigms of cutaneous tumorigenesis and metastasis.
In human skin, benign tumors outnumber malignant tumors, yet genetic studies of these are limited 3 . Rare inherited skin tumor syndromes such as CCS ( Fig. 1a-b) offer an opportunity to address this knowledge gap and novel molecular insights into cancer can be gained. They may reveal unexpected driver mutations 4 , highlight mechanisms that may be targetable with repurposed drugs developed for other cancers 5 , or refine models of tumor growth and 5 patterning. CCS patients develop multiple skin tumors named cylindroma, spiradenoma and trichoepithelioma, a histophenotypic spectrum of hair follicle-related tumors consistent with the hypothesis that they arise in hair follicle stem cells 6,7 . These tumors occur both at sunexposed and sun-protected sites. Infrequently, salivary gland tumors, pulmonary tumors 8 , malignant transformation 9 and metastasis with lethal outcomes can occur. 10 CYLD encodes a ubiquitin hydrolase enzyme involved in deubiquitination of lysine 63 10, 11 and Met 1 linked ubiquitin chains 12, 13 . In CCS families, germline mutations occur within the catalytic domains of CYLD and are frequently truncating 14 , predicting loss-of-function.
Loss of the wild-type parental allele (loss of heterozygosity-LOH) of CYLD is demonstrated in the majority of inherited cylindromas, consistent with its role as a recessive cancer gene 15 . 15 Genetic analysis of sporadic cylindromas, rare in the general population, have highlighted the fusion transcript MYB-NFIB in a subset of tumors 16 . Taken together with the recent finding of upregulated MYB in CCS tumors where MYB-NFIB fusions are absent, this supports MYB as a key downstream mediator of cylindroma pathogenesis following loss of CYLD 17 .
However beyond these drivers, CCS tumors studied using array-based comparative genomic 20 hybridization (CGH) demonstrate a paucity of DNA aberrations, restricted to copy neutral LOH of CYLD 15 , incongruent with the diverse histophenotypes seen within and across tumor samples.
Arguably, CYLD loss alone may be sufficient for tumorigenesis, via its role in negatively regulating oncogenic pathways; CYLD depletion using RNA interference first revealed its role in negatively regulating NF-kB signalling 10, 11, 18 . Corroborating this, murine CYLD knockout models develop skin papillomas following chemical carcinogenesis that demonstrate increased expression of NF-kB target genes such as cyclin D1 mediated by dysregulation of BCL3 19 . Furthermore, CYLD has been shown to negatively regulate various oncogenic signalling pathways that are also relevant in hair development in embryogenesis, 5 including Wnt 20 , Notch and TGF-b 6 .
In humans, recurrent loss of functional CYLD is reported in diverse cancers including: myeloma 21 , leukaemia 22,23 , hepatocellular carcinoma 24 , neuroblastoma 25 and pancreatic cancer 26 , consistent with its role as a tumor suppressor expressed ubiquitously in normal tissues. In CCS patients, increased Wnt signalling has been shown to be an 10 oncogenic dependency in cylindroma and spiradenoma tumors 7 . Histologically-organised cylindroma and histologically-disorganised spiradenoma represent extremes of a spectrum of histophenotype of the same tumor ( Fig. 1b and Supplementary Fig. 1a-c) . Transition from cylindroma to spiradenoma is associated with loss of expression of the negative Wnt signalling regulator Dickkopf 2 (DKK2) 7 . DNA methylation has been suggested as a 15 mechanism to account for loss of expression of DKK2 7 , however comprehensive genomic and methylomic profiling of CCS tumors has not been performed. The inability of CYLD knockout mouse models to recapitulate the human phenotype of cylindroma tumors, has further limited characterisation of the genetic drivers in CCS 27 .
Results
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Biallelic loss of CYLD drives CCS tumors. Thus, to delineate the genomic landscape of CCS in humans, we studied DNA from 11 fresh frozen tumors using whole genome sequencing (WGS) in two directly-related patients who had been under clinical follow-up for 35 years (Pt. 1 and 2) ( Fig. 1c and Supplementary Table 1 ). The average number of unique reads per 25 tumor and normal sample for WGS was 374,496,607, generating 35.5 mean fold coverage for all samples. We detected on average 1,381 substitutions per tumor sample (average 0.44 mutations per MB), 72 small insertions and deletions (indels), and 1 rearrangement, using WGS. Biallelic mutations in CYLD were a recurrent driver mutation, and no MYB-NFIB fusions were found, consistent with previous studies (Fig. 1b) 15 . Tumors demonstrated neither recurrent structural rearrangements nor recurrent copy number aberrations 5 ( Supplementary Fig. 2 ).
To validate these findings, we studied a further 31 tumors from 12 patients of 3 additional genotyped pedigrees using whole exome sequencing, given the lack of large structural rearrangements. We confirmed that CYLD biallelic loss was independent for each sample, reinforcing that each tumor arose independently: Loss of the wild-type allele was 10 observed either by LOH affecting 16q (31/42 tumors), or by a second mutation in CYLD (9/42), consistent with the loss of CYLD occurring across all benign and some malignant tumors in CCS.
Selection of mutated epigenetic modifiers in benign CCS tumors.
In addition to biallelic 15 mutations in CYLD, we discovered multiple mutations in epigenetic modifiers DNA methyltransferase 3a (DNMT3A) (n=6) and BCL6 co-repressor (BCOR) (n=8) in 12 tumors ( Fig. 2a, Supplementary Fig. 3a and Supplementary Table 2 ). In two tumors, both genes were mutated. BCOR mutations have also been reported to co-occur with DNMT3A in over 40% of BCOR-mutated cases of AML, suggesting a potential synergistic role in CCS 20 tumorigenesis 28 . Mutations in DNMT3A were predominantly missense mutations in the methyltransferase domain, but mutations in the zinc finger domains were also noted and have been reported previously in COSMIC ( Fig. 2a) 29 . Mutations in BCOR were predominantly frameshift mutations. Notably, different DNMT3A and BCOR driver mutations were seen in disparate tumors in patients 1 and 4, suggesting that convergent evolution drives tumorigenesis through epigenetic mechanisms in this cutaneous syndrome.
Interestingly, variant allele frequencies of DNMT3A and BCOR mutations ranged from 0.05-0.42 - Fig. 2b ), suggesting that intra-tumoral clonal heterogeneity may occur in these tumors. To explore this possibility, targeted deep sequencing (TDS; average coverage of 5 >500x) of DNMT3A and BCOR was performed on additional material taken from further tissue sections of nine tumors studied above. This confirmed the presence of intratumoral heterogeneity of these putative driver mutations, with two distinct mutant clones or more found to co-occur within the same tumor in six samples (PD37330a,c,g,i, PD40536d, PD40537a ) (Fig 2c and Supplementary Table 1 ). 10 To investigate whether DNMT3A mutational heterogeneity correlated with CCS tumor histophenotypes, we studied five tumors which contained intra-tumoral cylindroma and spiradenoma ( Fig. 2d and Supplementary Fig. 4a,b) . DNA was extracted from microdissected cylindroma and spiradenoma regions and TDS was performed. In three tumors, there was an identical DNMT3A mutation in both regions. In two tumors, there was 15 heterogeneity between the histophenotypes, with private mutations in each regions, suggesting that multiple DNMT3A mutant clones of different sizes exist within tumors.
Mutated DNMT3A2 epigenetically dysregulates Wnt/ß-catenin signalling.
To explore the functional relevance of mutations in DNMT3A and BCOR in CCS tumors, RNA sequencing 20 was performed in 16 tumors. This revealed increased expression of the short isoform of DNMT3A, called DNMT3A2, in 15 tumors compared to four perilesional skin controls ( Fig.   3a ). DNMT3A protein expression was also increased in CCS tumors compared to control skin and hair, and regions of heterogeneity were observed between islands of cylindroma ( Fig. 2e and Supplementary Fig. 5a,b ) in-keeping with reported mutational heterogeneity.
BCOR was expressed at similar levels in both control and tumor tissue ( Supplementary Fig.   3b ).
To assess the impact of DNMT3A mutations on methylation patterns, eight samples genotyped by TDS were studied using genome-wide DNA methylation arrays. Unsupervised clustering of the 250 most variably methylated loci revealed a distinct cluster comprising five 5 tumors with predicted DNMT3A2 isoform specific mutations ("DNMT3A2-mutated") ( Fig.   3b ). Comparison of these two clusters, revealed 1512 differentialy hypomethylated regions of contiguous probes in "DNMT3A2-mutated" tumors. Network analysis of these regions in "DNMT3A2-mutated" tumors identified the highest-ranked network to be functionally related to ß-catenin (p<1 x 10 -45 ) ( Supplementary Fig. 6 ). Taking this together with prior data that 10 DNMT3A has been shown to preferentially methylate Wnt/ß-catenin signalling pathway genes 30 , we assessed whether there was a relationship between expression of DNMT3A and expression of nuclear ß-catenin ( Fig. 3c) . Interestingly, this showed a co-relationship, where cells with reduced DNMT3A expression also demonstrated increased nuclear ß-catenin.
These data support a mechanistic model where DNMT3A2 isoform specific mutation 15 selectively alters methylation on Wnt signalling genes, affecting transcriptional co-activator ß-catenin, which confers an oncogenic advantage in CCS tumor cells with known Wnt dependency. revealed other family members that also carried this variant ( Supplementary Table 3) although their tumors did not have biallelic MBD4 loss and thus did not have the associated mutational signature. The observed burden and pattern of mutagenesis was consistent with MBD4's role as a DNA glycosylase safeguarding the integrity of methylated CpGs from deamination. Notably, additional driver mutations detected included epigenetic modifiers, 10 KDM6A and CREBBP. Tumor suppressors NOTCH2 and BAP1 were also noted to be driver mutations.
Malignant CCS tumors carry additional epigenetic modifier mutations. Malignant
Poorly differentiated adenocarcinoma (PD40536c) has not been reported in CCS and presented on the breast of a female CCS patient at age 47. The patient had extensive staging scans, mammograms and biopsies of breast cylindromas, and has been followed up for 3 15 years with no evidence of a non-cutaneous primary tumor. This tumor had driver mutations in TP53 and the epigenetic modifier EP300. Strikingly, this did not demonstrate LOH for CYLD. The BCAC-LG (PD40545a) tumor demonstrated a frameshift mutation in BCOR.
The atypical spiradenocarcinoma (PD40540a) did not show any changes apart from CYLD LOH. The BCC (PD45044c) demonstrated a PTCH driver mutation and CYLD LOH, 20 consistent with genetic features of BCC 32 . It also demonstrated the highest number of coding substitutions (1287) in our cohort, comprising the UV signature, in contrast to benign trichoepithelioma also arising on the face of the same patient.
Mutation analysis tracks origin of pulmonary cylindromas to the skin.
To investigate mutational mechanisms that may give rise to the mutations detected in CCS patients, we compared the mutational signatures in tumors with identical histological types at intermittently sun-exposed and typically sun-protected sites 33 (Fig. 4a) . Two tumors from the torso demonstrated substitution signature 7 (n=2; PD37331a,i) consistent with UV 5 exposure. By contrast, we did not find evidence of signature 7 and found the presence of mutational signatures 1 (associated with deamination of methylated cytosines) and 5 (unknown etiology) in sun-protected tumors from pubic and perianal sites (n=4;
PD37330c,e,g and PD37331c) and some intermittently sun-exposed tumors from the breast and torso (n=2). We surmise that in CCS, additional mechanisms other than UV are relevant 10 to development of skin cancer.
We next investigated the concept of "benign metastases" seen in some patients with CCS, who develop multiple pulmonary cylindromas without typical features of malignancy 8 .
We studied four pulmonary cylindromas that had benign histological features from patients 1 and 2, who were both ex-smokers. They did not have evidence of lymph node disease, 15 hepatic or bone metastases (Fig. 4b) . Tumor phylogenetic analysis revealed that multiple pulmonary lesions from patient 2 shared 1,848 substitutions suggesting that these geographically-separated lesions that seeded in the lung, had a common origin (Fig. 4c) . We found that the UV mutation signature 7 was present in the shared mutations, and thus tracked the origin of these pulmonary lesions to sun-exposed skin. Lastly, we found recurrent, E17K 20 AKT1 oncogenic mutations in multiple lung cylindromas in each patient, and in both patients independently as well. This is interesting for two reasons: First, although the numbers are small, this suggests that AKT1 mutations likely arose prior to seeding in the lung. The AKT1 mutations may confer lung tissue tropism for cylindromas. Second, this recurrent E17K AKT1 mutation is clinically-relevant and targetable. As drugs have been developed to target AKT1 mutations in a diverse range of solid tumors 34 , this finding further creates therapeutic opportunities for this limiting secondary complication of CCS.
Discussion
This work delineates the mutational landscape of CCS. It highlights the presence of 5 distinct DNMT3A and BCOR mutations in different tumor sites of the same patient (intertumor heterogeneity) and different geographic sites within the same tumor (intra-tumor heterogeneity), which suggests strong convergent evolution (Supplementary Fig. 8 ) towards epigenetic dysregulation in this orphan disease where no medical treatments are available.
Due to the clinical interest in mutated epigenetic modifiers in leukemia, strategies used to 10 target DNMT3A mutant hematological malignancies may be relevant to CCS 35 . The accessibility of CCS skin tumors lend themselves to direct drug delivery, which may be an attractive route avoiding systemic side effects, as suggested by the methodology of a recent early phase clinical trial in CCS 5 .
In addition, we reveal mutational synergy between CYLD loss and epigenetic modifiers such 15 as DNMT3A, through NF-kB and Wnt signalling pathways. This may have broader relevance for common BCC, where CYLD is transcriptionally repressed 36 , and Wnt/ ß-catenin signalling is pathogenic 37 . Notably, a recent study reported the presence of mutations in DNMT3A (10%) and BCOR (18%) in the exomes of 293 BCCs; functional studies are required to investigate the clinical significance of this finding 32 . Finally, we uncategorically 20 demonstrate that the multiple benign pulmonary lesions in this syndrome have a clonal, cutaneous ancestral origin -reinforcing the concept of benign metastases as a clinical phenotype.
Materials and Methods
Patients and samples
Retrospective review of the case notes and radiological data of 15 genotyped CYLD mutation carriers that were under follow up between 1 July 2013 and 1 July 2017 was performed. Skin 5 and lung samples were obtained from patients with signed consent, and details of samples are shown in Table 1 . Research ethics committee approval was obtained for this work (REC Ref:
06/Q1001/59; 08/H0906/95+5). 
Histology and immunohistochemistry-
ASCAT copy number analysis
Allele-specific copy number analysis of tumors analyzed by WGS was performed using ASCAT (v2.1.1) as described previously 33 . ASCAT takes non-neoplastic cellular infiltration and overall tumor ploidy into consideration, to generate integer-based allele-specific copy number profiles for the tumor cells. Copy number values and estimates of aberrant tumor cell fraction provided by ASCAT were in put into the CaVEMan substitution algorithm for WGS.
In addition, ASCAT segmentation profiles were used to establish the presence of loss of heterozygosity across CYLD and relevant mutated cancer driver genes. 5 Somatic mutations present in known cancer genes (Cancer gene census https://cancer.sanger.ac.uk/census) were reviewed to identify those which were likely to be driver mutations. Mutations were deemed to be potential driver mutations if they were consistent with the type of mutations found in a particular cancer gene; that is, inactivating mutations in tumor suppressor genes (including nonsense, frameshift, essential splice site 10 mutations and recurrent missense) and recurrent mutations in dominant oncogenes. Recurrent mutations were determined by reference to reported mutation frequency in the COSMIC database (https://cancer.sanger.ac.uk/cosmic). 15 The contributions of substitution signatures for WGS samples were determined as follows:
Identification of driver mutations
Mutational signature analysis
The substitution profile is described as a 96-channel vector. For each mutation, of which there are 6 substitution classes of C>A, C>G, C>T, T>A, T>C and T>G, the flanking 5' and 3' sequence context is taken into account giving a total of 96 channels. A given set of mutational signatures was fitted into the mutational profile of each sample to estimate the 20 exposure of each of the given signatures in that sample. The fitting algorithm (Degasperi et al., in preparation) detects the presence of mutational signatures with confidence, using a bootstrap approach to calculate the empirical probability of an exposure to be larger or equal to a given threshold (i.e. 5% of mutations of a sample). Here, we first used 30 COSMIC signatures (https://cancer.sanger.ac.uk/cosmic/signatures) to fit into each sample, and then chose the first three signatures with highest confidence, which are signature 1, 5 and 7, to do the final fitting.
For highly mutated malignant samples (the spiradenocarcinoma (PD36119a) and the BCC (PD40544c)), the mutation burden was orders of magnitude higher than other non-malignant 5 tumors that were exome-sequenced. We were able to use cosine similarity between the overall 96 channel profile and COSMIC signature to confirm the presence of particular mutational signatures in the relevant sample. The cosine similarity between each malignant sample and the suspected COSMIC signature was high: For PD36119a, cosine similarity to COSMIC signature 1 was 0.92 and for PD40544c cosine similarity to the UV light signature, 10 COSMIC signature 7, was 0.98. Figure S4 ) where intratumoral clonal variation was studied across distinct histophenotypic regions, variant call thresholds were relaxed, and all non-synonymous variants called were confirmed by visualizing aligned read data using Integrated Genomics Viewer (IGV; v2.3). These variants were included if aligned reads supported the variant calls.
Targeted sequencing
Transcriptomic analyses
RNA was extracted from 16 tumor samples and 4 control samples and stranded preparation was performed using the Illumina stranded mRNA kit as previously described 5 . Libraries were prepared and sequenced using an Illumina Hiseq 2500, giving 15 million paired end 5 reads per sample which were 100 bp in length. FASTQ files were aligned using the splice aware aligner program STAR to generate alignment files 39 . The read counts for each sample file were counted using the R package Subread 40 . Differential gene expression analysis was carried out using the package DeSeq2 41 .
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Methylation assay
We assessed genome-wide DNA methylation in seven tumor samples with the Illumina Methylation EPIC microarray (Illumina, San Diego, CA, USA). DNA methylation assays were performed as per the standard manufacturer's protocol by MWG (Aros -Denmark).
Methylation array processing, functional normalization 42 and quality control checks were 15 implemented using the R package minfi 43 . Differentially methylated probes were identified using minfi. Differentially methylated regions spanning multiple probes were identified using bumphunter 44 ; these regions were visualized using Gviz 45 Fig. 4 UV signature analysis reveals distinct mutational mechanisms in skin and tracks origin of lung tumors. a, Examples of intermittently sun-exposed and sun-protected CCS tumors demonstrate differing mutational profiles. Mutational signature analysis reveals UV-related signature 7 in sun-exposed tumors only. b, In one patient with three pulmonary lesions, a phylogenetic analysis reveals 1,848 mutations were shared in common and showed a UV signature. Hence these benign pulmonary lesions had a common origin, likely-sunexposed skin.
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